The Ensign Group, Inc.
ENSG
$174.92
-1.65%
The Ensign Group, Inc. is a healthcare services company that provides post-acute care through skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations across the United States. As a leading operator in the fragmented skilled nursing industry, Ensign differentiates itself through a decentralized regional management model and a captive REIT (Standard Bearer) that owns properties, enabling strategic acquisitions and operational efficiencies. The current investor narrative centers on the company's aggressive acquisition strategy and operational improvements, which have driven strong revenue growth and raised guidance, though the stock has faced recent volatility due to broader market concerns and sector-specific pressures.…
ENSG
The Ensign Group, Inc.
$174.92
Related headlines
Investment Opinion: Should I buy ENSG Today?
Based on the analysis, ENSG is rated a Buy. The company's strong revenue growth of 18.4% YoY, improving margins, and analyst target upside of 27.2% support this rating. The forward PE of 20.23x is reasonable given the expected earnings growth, and the stock's defensive nature with a beta of 0.694 adds to its appeal.
Sign up to view all
ENSG 12-Month Price Forecast
The AI model is bullish on ENSG due to its strong growth fundamentals, improving profitability, and attractive analyst targets. However, the high valuation and leverage warrant caution. The stance would be upgraded to high confidence if the company delivers another quarter of 18%+ revenue growth and maintains margins. Conversely, a downgrade to neutral would occur if revenue growth decelerates below 10% or if regulatory risks materialize.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Ensign Group, Inc.'s 12-month outlook, with a consensus price target around $220.00 and implied upside of +25.8% versus the current price.
Average Target
$220.00
0 analysts
Implied Upside
+25.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$207 - $230
Analyst target range
Analyst coverage is limited, with only 5 analysts providing targets, and the consensus recommendation is 'none' due to mixed ratings. The average target price is $220.00, implying a 27.2% upside from the current price of $172.98. The target range spans from $207.00 to $230.00, with the low target still 19.7% above the current price, indicating that even the most bearish analyst sees significant value. The high target of $230.00 assumes continued acquisition-driven growth and margin expansion, while the low target reflects potential headwinds from regulatory changes or operational disruptions. Recent ratings have been stable, with no upgrades or downgrades in the past three months, suggesting a wait-and-see approach among analysts.
Bulls vs Bears: ENSG Investment Factors
Ensign Group presents a compelling growth story with strong revenue acceleration, improving margins, and a defensive healthcare profile. However, the stock trades at a premium valuation, carries high debt, and faces regulatory risks. The bull case is supported by robust fundamentals and analyst upside, while the bear case highlights valuation and leverage concerns. Currently, the bull case has stronger evidence given the consistent growth and raised guidance, but the key tension is whether the market will continue to reward the growth at current multiples or if a slowdown in acquisitions or regulatory headwinds will trigger a re-rating.
Bullish
- Strong Revenue Growth: Q1 2026 revenue grew 18.4% YoY to $1.389B, with sequential growth from $1.361B in Q4 2025. This acceleration is driven by the Skilled Services segment, which contributed $1.331B, and reflects successful acquisition integration and organic improvements.
- Raised Guidance and Positive News: Recent Zacks article highlights robust acquisition strategy and operational improvements, with raised guidance. This suggests management confidence in sustaining growth, supported by the 18.4% YoY revenue growth and improving margins.
- Analyst Targets Show Upside: Average analyst target is $220, implying 27.2% upside from current $172.98. Even the low target of $207 is 19.7% above current price, indicating that analysts see significant value despite recent volatility.
- Improving Profitability: Net margin improved to 7.17% in Q1 2026 from 6.84% in Q1 2025, and operating margin rose to 8.99% from 8.64%. This indicates operational leverage and efficient cost management, supporting earnings growth.
Bearish
- High Valuation Multiples: Trailing PE of 29.03x and forward PE of 20.23x are premium to industry averages. The PEG ratio of 2.06 suggests the stock is overvalued relative to its growth rate, which could lead to multiple compression if growth slows.
- Significant Drawdown and Volatility: Stock has fallen 19.2% over the past 6 months and 31.8% from its 52-week high. This volatility indicates investor uncertainty and potential for further downside if market conditions worsen.
- High Debt Levels: Debt-to-equity ratio of 1.86 is elevated, indicating significant leverage. This increases financial risk, especially if interest rates rise or cash flows decline, potentially impacting the company's ability to fund acquisitions.
- Dependence on Government Reimbursement: Majority of revenue comes from Medicare and Medicaid, making the company vulnerable to policy changes, reimbursement rate cuts, or regulatory reforms. Any adverse changes could significantly impact profitability.
ENSG Technical Analysis
Over the past year, ENSG has delivered a modest gain of 0.22%, but this masks significant intra-year volatility. The stock currently trades at $172.98, which is 79.3% of its 52-week range (low of $141.58, high of $218.00), indicating it is well off its highs but above its lows. This positioning suggests the stock is in a recovery phase after a sharp decline, with the current price closer to the midpoint of its range, reflecting a balance between value-seeking buyers and lingering bearish sentiment.
Beta
0.69
0.69x market volatility
Max Drawdown
-31.8%
Largest decline past year
52-Week Range
$142-$218
Price range past year
Annual Return
+5.4%
Cumulative gain past year
| Period | ENSG Return | S&P 500 |
|---|---|---|
| 1m | -4.1% | -0.6% |
| 3m | +13.8% | +2.1% |
| 6m | -12.6% | +17.6% |
| 1y | +5.4% | +15.7% |
| ytd | +0.6% | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ENSG Fundamental Analysis
Ensign's revenue trajectory remains robust, with Q1 2026 revenue of $1.389 billion, up 18.4% year-over-year, and sequential growth from $1.361 billion in Q4 2025. The multi-quarter trend shows accelerating growth, with revenue rising from $1.173 billion in Q1 2025 to $1.389 billion in Q1 2026, driven primarily by the Skilled Services segment, which contributed $1.331 billion in the latest quarter. This growth is supported by an aggressive acquisition strategy and organic improvements, positioning the company for continued expansion.
Quarterly Revenue
$1.4B
2026-03
Revenue YoY Growth
+18.4%
YoY Comparison
Gross Margin
16.4%
Latest Quarter
Free Cash Flow
$406100000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ENSG Overvalued?
Given that Ensign is profitable, the PE ratio is the most appropriate valuation metric. The trailing PE stands at 29.03x, while the forward PE is 20.23x, implying the market expects significant earnings growth. The gap between trailing and forward PE suggests a forward earnings growth rate of approximately 43%, which is optimistic but supported by the company's recent growth trajectory and raised guidance.
PE
29.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 17x~30x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
24.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Ensign carries a debt-to-equity ratio of 1.86, indicating significant leverage that could strain cash flows if interest rates rise or if acquisitions underperform. The company's net margin is thin at 6.8%, leaving little room for cost inflation or reimbursement cuts. Additionally, the stock's high beta of 0.694 does not fully shield it from market downturns, as evidenced by the 19.2% decline over the past six months. Cash flow generation is positive with $406M in TTM free cash flow, but this could be impacted by integration costs or unexpected operational issues.
FAQ
The key risks include: 1) Regulatory risk: Dependence on Medicare/Medicaid reimbursement, which could be cut, impacting revenue. 2) Financial risk: High debt-to-equity ratio of 1.86 increases vulnerability to interest rate hikes. 3) Operational risk: Integration of acquisitions may fail, leading to write-downs. 4) Market risk: High valuation multiples could compress if growth disappoints, as seen in the 31.8% drawdown from highs. These risks are ranked by severity, with regulatory changes being the most impactful.
The 12-month forecast is bullish, with a base case target of $200-$220 (50% probability), bull case of $220-$230 (30%), and bear case of $141-$170 (20%). The most likely scenario is the base case, assuming continued revenue growth of 15-18% and stable reimbursement. The stock is expected to recover from its recent dip and trade near the average analyst target of $220.
ENSG is trading at a premium to its historical averages, with a trailing PE of 29.03x and forward PE of 20.23x. The PEG ratio of 2.06 suggests the stock is overvalued relative to its growth rate. However, the market is pricing in significant earnings growth, which is supported by the company's recent performance. Compared to the healthcare sector, the valuation is high, but the growth prospects justify a premium. The stock is fairly valued if the company achieves its growth targets, but overvalued if growth slows.
Yes, ENSG is a good buy for investors with a long-term horizon and tolerance for volatility. The stock offers a 27.2% upside to the average analyst target of $220, supported by strong revenue growth of 18.4% YoY and improving margins. However, the high valuation (PE 29x) and debt levels (D/E 1.86) pose risks. It is best suited for investors who believe in the company's acquisition strategy and can withstand short-term fluctuations.
ENSG is more suitable for long-term investment due to its growth trajectory and defensive characteristics. The stock's beta of 0.694 indicates lower volatility, but it has experienced significant drawdowns, making it risky for short-term trading. With a dividend yield of 0.14%, income is minimal, so the focus is on capital appreciation. A minimum holding period of 3-5 years is recommended to allow the acquisition strategy to play out and for the market to recognize the company's value.